Chinese biopharmaceutical firm Pyrotech Therapeutics has secured 700 million yuan ($97.2 million) in a Series A financing round co-led by state-owned investment firms SDIC Venture Capital and China Venture Capital, according to a company release on Monday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
